UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma

PloS one, 2024-03, Vol.19 (3), p.e0299820

2024

Volltextzugriff (PDF)

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas

Archives of pathology & laboratory medicine (1976), 2017-12, Vol.141 (12), p.1697-1704

2017

Volltextzugriff (PDF)

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

PloS one, 2019-01, Vol.14 (1), p.e0210608

2019

Volltextzugriff (PDF)

Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response

Cell death & disease, 2023-08, Vol.14 (8), p.561-13, Article 561

2023

Volltextzugriff (PDF)

Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

International journal of cancer, 2013-05, Vol.132 (10), p.2339-2348

2013

Volltextzugriff (PDF)

Publisher Correction: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor‑like population

Acta neuropathologica communications, 2024-06, Vol.12 (1), p.107-3, Article 107

2024

Volltextzugriff (PDF)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.142-14, Article 142

2019

Volltextzugriff (PDF)

Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population

Acta neuropathologica communications, 2023-03, Vol.11 (1), p.50-30, Article 50

2023

Volltextzugriff (PDF)

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Nuclear medicine and biology, 2010-10, Vol.37 (7), p.785-794

2010

Volltextzugriff (PDF)

Th17 Immunity in the Colon Is Controlled by Two Novel Subsets of Colon-Specific Mononuclear Phagocytes

Frontiers in immunology, 2021-04, Vol.12, p.661290

2021

Volltextzugriff (PDF)

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

Clinical cancer research, 2018-09, Vol.24 (17), p.4175-4186

2018

Volltextzugriff (PDF)

D2C7 CAR: A novel CAR T cell that simultaneously targets wildtype EGFR and its mutant isoform EGFRvIII for treatment of glioma

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.122-122.03

2022

Volltextzugriff (PDF)

GMab-1, a high-affinity anti-3′-isoLM1/3′,6′-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice

Biochemical and biophysical research communications, 2010-01, Vol.391 (1), p.750-755

2010

Volltextzugriff (PDF)

LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION

Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i58-i58

2023

Volltextzugriff (PDF)

EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi176-vi176

2021

Volltextzugriff (PDF)

Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition

Cancer cell, 2022-05, Vol.40 (5), p.439-440

2022

Volltextzugriff (PDF)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii365-iii365

2020

Volltextzugriff (PDF)

SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION

Neuro-oncology advances, 2023-08, Vol.5 (Supplement_3), p.iii30-iii30

2023

Volltextzugriff (PDF)

Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display

Protein engineering, design and selection, 2017-09, Vol.30 (9), p.639-647

2017

Volltextzugriff (PDF)

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial

Applied microbiology and biotechnology, 2017-04, Vol.101 (7), p.2747-2766

2017

Volltextzugriff (PDF)

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e14015-e14015

2022

Volltextzugriff (PDF)

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.102-102

2017

Volltextzugriff (PDF)

Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.74-74

2017

Volltextzugriff (PDF)

Development and validation of a cell-based fluorescent method for measuring antibody affinity

Journal of immunological methods, 2017-03, Vol.442, p.49-53

2017

Volltextzugriff (PDF)

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

Science translational medicine, 2023-02, Vol.15 (682), p.eabn5649

2023

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(49)
Dissertationen
(1)

Sprache

Englisch
(50)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response

Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

Publisher Correction: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor‑like population

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Th17 Immunity in the Colon Is Controlled by Two Novel Subsets of Colon-Specific Mononuclear Phagocytes

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

D2C7 CAR: A novel CAR T cell that simultaneously targets wildtype EGFR and its mutant isoform EGFRvIII for treatment of glioma

GMab-1, a high-affinity anti-3′-isoLM1/3′,6′-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice

LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION

EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA

Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY

SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION

Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG)

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors

Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4

Development and validation of a cell-based fluorescent method for measuring antibody affinity

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

Suchergebnisse filtern